98 results
8-K
EX-10.1
FGEN
FibroGen, Inc.
7 Jun 24
Submission of Matters to a Vote of Security Holders
4:12pm
). If a Participant’s Continuous Service is suspended pending an investigation of the existence of Cause, all of the Participant’s rights under the Option … or SAR will also be suspended during the investigation period.
(l)Non-Exempt Employees. If an Option or SAR is granted to an Employee who is a non
8-K
EX-99.1
z6eg9e6
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
8-K
EX-99.1
3i3djc4y
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
EX-99.1
z6uiu9tlhq870xxeo84
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
fcdckqne
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
70kiowlu
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
es5pflspjchg3w465jg9
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am